• LAST PRICE
    6.1100
  • TODAY'S CHANGE (%)
    Trending Up0.4900 (8.7189%)
  • Bid / Lots
    5.9500/ 10
  • Ask / Lots
    6.3700/ 3
  • Open / Previous Close
    5.7600 / 5.6200
  • Day Range
    Low 5.6301
    High 6.4500
  • 52 Week Range
    Low 1.5500
    High 8.4399
  • Volume
    266,032
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 5.62
TimeVolumePULM
09:32 ET98495.78
09:35 ET6005.79
09:37 ET3005.8
09:39 ET23325.746129
09:42 ET19255.79
09:46 ET77285.8399
09:48 ET26945.85
09:50 ET3005.77
09:51 ET3465.75
09:53 ET24085.85
09:55 ET17005.85
09:57 ET2695.91
10:00 ET95926.025
10:02 ET24406
10:04 ET7366.0077
10:06 ET11856.0289
10:08 ET57006.14
10:09 ET38056.19
10:11 ET201006.24
10:13 ET1006.28
10:15 ET8146.26
10:18 ET26776.1742
10:20 ET7006.11
10:22 ET15256.01
10:24 ET11256.07
10:26 ET2006.07
10:29 ET2006.07
10:31 ET1506.07
10:33 ET45006.0155
10:36 ET3006.07
10:38 ET5006.0638
10:40 ET30876.1478
10:44 ET10806.15
10:45 ET2006.02
10:47 ET2006.0322
10:49 ET7146.0122
10:51 ET2006.09
10:54 ET6006.165
10:56 ET3006.17
10:58 ET32006.2006
11:00 ET1586.1698
11:02 ET2006.2132
11:03 ET6006.1492
11:05 ET1246.185
11:07 ET7006.2
11:12 ET3006.25
11:14 ET9726.25
11:16 ET42006.35
11:18 ET88976.285
11:20 ET62556.2
11:21 ET7286.12
11:23 ET5776.12
11:25 ET1006.12
11:27 ET2506.12
11:30 ET11626.12
11:34 ET1506.06
11:36 ET1636.12
11:39 ET3006.172
11:41 ET30006.1346
11:43 ET1506.12
11:45 ET3456.1024
11:56 ET143966.05
11:59 ET6006.08
12:01 ET3286.05
12:03 ET1006.0129
12:17 ET3506.0064
12:24 ET2006.05
12:35 ET1656
12:37 ET2006.1
12:39 ET24106.026
12:46 ET10006.13
12:51 ET8016.1
12:55 ET70966.12
01:02 ET10005.972
01:06 ET2005.9798
01:08 ET1006.01
01:18 ET52555.87
01:24 ET9005.79
01:26 ET21005.965
01:27 ET61005.79
01:36 ET1005.935
01:40 ET11006.0699
01:47 ET41405.9503
01:51 ET7006.0488
01:58 ET2005.84
02:02 ET8885.92
02:05 ET2005.99
02:12 ET40886.1
02:14 ET1006.0716
02:16 ET3116.07
02:20 ET1006.055
02:25 ET1006.09
02:32 ET13006.02
02:34 ET55946.13
02:36 ET1356.15
02:43 ET1005.93
02:50 ET7736.15
02:59 ET3006.1817
03:03 ET17506.225
03:06 ET1006.225
03:08 ET7006.2024
03:10 ET23296.1605
03:17 ET6506.25
03:21 ET1006.24
03:24 ET5006.19
03:26 ET6006.19
03:28 ET1256.1597
03:30 ET1806.2328
03:32 ET36886.29
03:33 ET206366.345
03:35 ET81836.29
03:37 ET99886.185
03:39 ET7556.1966
03:44 ET2556.1195
03:48 ET22956.18
03:50 ET17086.14
03:51 ET7006.155
03:53 ET50006.145
03:55 ET1296.1139
03:57 ET1006.1
04:00 ET23856.11
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPULM
Pulmatrix Inc
20.5M
-2.3x
---
United StatesBOLT
Bolt Biotherapeutics Inc
21.8M
-0.3x
---
United StatesDRRX
DURECT Corp
28.0M
-1.6x
---
United StatesCIPI
Correlate Energy Corp
6.4M
-0.1x
---
United StatesSPRB
Spruce Biosciences Inc
20.2M
-0.5x
---
United StatesRDHL
Redhill Biopharma Ltd
8.2M
0.0x
---
As of 2024-11-21

Company Information

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

Contact Information

Headquarters
945 CONCORD STREET, SUITE 1217FRAMINGHAM, MA, United States 01701
Phone
781-357-2333
Fax
302-636-5454

Executives

Independent Chairman of the Board
Michael Higgins
Interim Chief Executive Officer, Interim Chief Financial Office
Peter Ludlum
Vice President - Finance
Michelle Siegert
Independent Director
Richard Batycky
Independent Director
Todd Bazemore

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$20.5M
Revenue (TTM)
$10.0M
Shares Outstanding
3.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.23
EPS
$-2.64
Book Value
$4.93
P/E Ratio
-2.3x
Price/Sales (TTM)
2.1
Price/Cash Flow (TTM)
---
Operating Margin
-100.31%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.